Key Points
- CFO Stephen Carey sold 2,850 ANI Pharmaceuticals shares at an average price of $72.80, generating $207,480. The transaction occurred under a pre-arranged Rule 10b5-1 trading plan, leaving him with 171,843 shares.
- ANI Pharmaceuticals reported strong quarterly results, with revenue rising 25.8% year over year to $266.04 million and EPS of $2.21, exceeding analyst expectations of $2.04.
- Analyst sentiment remains moderately bullish, with an average rating of “Moderate Buy” and a consensus price target of $105.83, although several firms recently lowered ratings or price targets.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CFO Stephen Carey sold 2,850 shares of ANI Pharmaceuticals stock in a transaction on Monday, August 31st. The stock was sold at an average price of $72.80, for a total transaction of $207,480.00. Following the sale, the chief financial officer owned 171,843 shares in the company, valued at $12,510,170.40. This represents a 1.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ANI Pharmaceuticals Stock Performance
NASDAQ ANIP opened at $71.92 on Wednesday. ANI Pharmaceuticals, Inc. has a twelve month low of $70.15 and a twelve month high of $99.50. The stock has a market cap of $1.65 billion, a P/E ratio of 15.50 and a beta of 0.45. The company's 50-day simple moving average is $79.31 and its 200 day simple moving average is $78.56. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same quarter last year, the company earned $1.80 EPS. ANI Pharmaceuticals's revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages have recently weighed in on ANIP. Canaccord Genuity Group lowered their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research note on Monday, August 10th. Zacks Research cut ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 14th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Guggenheim dropped their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a research note on Monday, August 10th. Finally, Weiss Ratings cut ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, ANI Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $105.83.
Check Out Our Latest Stock Analysis on ANIP
Institutional Investors Weigh In On ANI Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals during the first quarter valued at approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of ANI Pharmaceuticals by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company's stock worth $736,000 after purchasing an additional 470 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock worth $3,235,000 after purchasing an additional 423 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $2,706,000. Finally, Norges Bank acquired a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at approximately $625,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
